A Study of Experimental Tucatinib vs. Placebo Combined With Ado-trastuzumab Emtansine (T-DM1) for HER2+ Breast Cancer
HER2-positive Breast Cancer Seattle Genetics Breast Neoplasms Tucatinib Tucatinib + T-DM1
Lead Scientist at UC Davis
- Mili Arora, MD
Assistant Professor, Hematology and Oncology. Authored (or co-authored) 10 research publications.